The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis

BMC Nephrology

Luca Valenti⁵  Silvia Fargion⁵  Piergiorgio Messa¹  Clara Camaschella³  Daniela Toniolo⁴  Giovanna Como¹  Paola Dongiovanni⁵  Michela Traglia⁴  Carlo Alfieri¹  Natascia Campostrini²  Raffaela Rametta⁵  Domenico Girelli²  Serena Pelusi⁵ 

[1]Nephrology, Fondazione IRCCS Ca’ Granda Ospedale Policlinico, Milano, Italy

[2]Department of Medicine, Internal Medicine, Università di Verona, Verona, Italy

[3]San Raffaele Research Institute, Università Vita-Salute, Milano, Italy

[4]Institute of Molecular Genetics, CNR Pavia, Italy

[5]Department of Pathophysiology and Transplantation, Internal Medicine, Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Policlinico Milano, Milano, Italy

关键词: Tmprss6;    Matriptase-2;    Hfe gene;    Hepcidin;    Hemodialysis;    Iron;    Inflammation;    Genetics;    Erythropoietin;    Chronic kidney disease;    Anemia;   

Others  :  1082990
DOI  :  10.1186/1471-2369-14-48

 received in 2012-09-07, accepted in 2013-02-14,  发布年份 2013

【 摘 要 】

Background

Aim of this study was to evaluate whether the A736V TMPRSS6 polymorphism, a major genetic determinant of iron metabolism in healthy subjects, influences serum levels of hepcidin, the hormone regulating iron metabolism, and erythropoiesis in chronic hemodialysis (CHD).

Methods

To this end, we considered 199 CHD patients from Northern Italy (157 with hepcidin evaluation), and 188 healthy controls without iron deficiency, matched for age and gender. Genetic polymorphisms were evaluated by allele specific polymerase chain reaction assays, and hepcidin quantified by mass spectrometry.

Results

Serum hepcidin levels were not different between the whole CHD population and controls (median 7.1, interquartile range (IQR) 0.55-17.1 vs. 7.4, 4.5-17.9 nM, respectively), but were higher in the CHD subgroup after exclusion of subjects with relative iron deficiency (p = 0.04). In CHD patients, the A736V TMPRSS6 polymorphism influenced serum hepcidin levels in individuals positive for mutations in the HFE gene of hereditary hemochromatosis (p < 0.0001). In particular, the TMPRSS6 736 V variant was associated with higher hepcidin levels (p = 0.017). At multivariate analysis, HFE and A736V TMPRSS6 genotypes predicted serum hepcidin independently of ferritin and C reactive protein (p = 0.048). In patients without acute inflammation and overt iron deficiency (C reactive protein <1 mg/dl and ferritin >30 ng/ml; n = 86), hepcidin was associated with lower mean corpuscular volume (p = 0.002), suggesting that it contributed to iron-restricted erythropoiesis. In line with previous results, in patients without acute inflammation and severe iron deficiency the “high hepcidin” 736 V TMPRSS6 variant was associated with higher erythropoietin maintenance dose (p = 0.016), independently of subclinical inflammation (p = 0.02).

Conclusions

The A736V TMPRSS6 genotype influences hepcidin levels, erythropoiesis, and anemia management in CHD patients. Evaluation of the effect of TMPRSS6 genotype on clinical outcomes in prospective studies in CHD may be useful to predict the outcomes of hepcidin manipulation, and to guide treatment personalization by optimizing anemia management.

【 授权许可】

   
2013 Pelusi et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Paganini EP: Overview of anemia associated with chronic renal disease: primary and secondary mechanisms. Semin Nephrol 1989, 9:3-8.
• [2]Canavesi E, Valenti L: Modulation of Iron Metabolism and Hepcidin Release by HFE Mutations in Chronic Hemodialysis Patients: Pathophysiological and Therapeutic Implications. In Hemodialysis. - Different Aspects Edited by Maria Goretti P. Available from: http://www.intechopen.com/books/hemodialysis-different-aspects/modulation-of-iron-metabolism-and-hepcidin-release-by-hfe-mutations-in-chronic-hemodialysis-patients webcite ISBN 978-953-307-315-6
• [3]Babitt JL, Lin HY: Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010, 55:726-741.
• [4]Kalantar-Zadeh K, Rodriguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004, 19:141-149.
• [5]Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A: Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008, 28:115-121.
• [6]Valenti L, Girelli D, Valenti GF, Castagna A, Como G, Campostrini N, Rametta R, Dongiovanni P, Messa P, Fargion S: HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009, 4:1331-1337.
• [7]Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I: Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006, 108:1381-1387.
• [8]Kuragano T, Itoh K, Shimonaka Y, Kida A, Furuta M, Kitamura R, Yahiro M, Nanami M, Otaki Y, Hasuike Y: Hepcidin as well as TNF-{alpha} are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011, 26:2663-2667.
• [9]Malyszko J, Mysliwiec M: Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 2007, 30:15-30.
• [10]Morelle J, Labriola L, Jadoul M: Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009, 76:1116. author reply 1116
• [11]Costa E, Swinkels DW, Laarakkers CM, Rocha-Pereira P, Rocha S, Reis F, Teixeira F, Miranda V, do Sameiro Faria V, Loureiro A: Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol 2009, 122:226-229.
• [12]Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Carvalho F, Porto G: Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood 2008, 111:5727-5733.
• [13]Girelli D, Trombini P, Busti F, Campostrini N, Sandri M, Pelucchi S, Westerman M, Ganz T, Nemeth E, Piperno A, Camaschella C: A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 2011, 96:500-506.
• [14]Valenti L, Valenti G, Como G, Santorelli G, Dongiovanni P, Rametta R, Fracanzani AL, Tavazzi D, Messa PG, Fargion S: HFE Genotype Influences Erythropoiesis Support Requirement in Hemodialysis Patients: A Prospective Study. Am J Nephrol 2008, 28:311-316.
• [15]Valenti L, Valenti G, Como G, Burdick L, Santorelli G, Dongiovanni P, Rametta R, Bamonti F, Novembrino C, Fracanzani AL: HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. Am J Nephrol 2007, 27:101-107.
• [16]Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005, 16:3070-3080.
• [17]Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, Burdick L, Frugoni C, Fracanzani AL, Fargion S: Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 2011, 31:683-690.
• [18]Valenti L, Swinkels DW, Burdick L, Dongiovanni P, Tjalsma H, Motta BM, Bertelli C, Fatta E, Bignamini D, Rametta R: Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2010, 21:568-575.
• [19]Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, Winters A, Juan T, Li H, Begley CG, Molineux G: Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010, 115:3616-3624.
• [20]Traglia M, Girelli D, Biino G, Campostrini N, Corbella M, Sala C, Masciullo C, Vigano F, Buetti I, Pistis G: Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet 2011, 48:629-634.
• [21]Nai A, Pagani A, Silvestri L, Campostrini N, Corbella M, Girelli D, Traglia M, Toniolo D, Camaschella C: TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood 2011, 118:4459-4462.
• [22]Finberg KE: Iron-refractory iron deficiency anemia. Semin Hematol 2009, 46:378-386.
• [23]Benyamin B, Ferreira MA, Willemsen G, Gordon S, Middelberg RP, McEvoy BP, Hottenga JJ, Henders AK, Campbell MJ, Wallace L: Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet 2009, 41:1173-1175.
• [24]Chambers JC, Zhang W, Li Y, Sehmi J, Wass MN, Zabaneh D, Hoggart C, Bayele H, McCarthy MI, Peltonen L: Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 2009, 41:1170-1172.
• [25]Valenti L, Fracanzani A, Rametta R, Fraquelli M, Soverini G, Pelusi S, Dongiovanni P, Conte D, Fargion S: Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. J Hepatol 2012, 57:1319-1325.
• [26]Valenti L, Rametta R, Dongiovanni P, Motta BM, Canavesi E, Pelusi S, Pulixi EA, Fracanzani AL, Fargion S: The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease. PLoS One 2012, 7:e48804.
• [27]Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004, 19(Suppl 2):ii1-ii47.
• [28]Valenti L, Canavesi E, Galmozzi E, Dongiovanni P, Rametta R, Maggioni P, Maggioni M, Fracanzani AL, Fargion S: Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2010, 53:927-933.
• [29]Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, Poli A, Martinelli N, Lupo A, Olivieri O, Girelli D: Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol 2010, 2010:329646.
• [30]Campostrini N, Traglia M, Martinelli N, Corbella M, Cocca M, Manna D, Castagna A, Masciullo C, Silvestri L, Olivieri O: Serum levels of the hepcidin-20 isoform in a large general population: The Val Borbera study. J Proteomics 2012, 76:28-35.
• [31]Babitt JL, Lin HY: Mechanisms of anemia in CKD. J Am Soc Nephrol 2012, 23:1631-1634.
• [32]Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB: Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010, 5:1010-1014.
• [33]Bratescu LO, Barsan L, Munteanu D, Stancu S, Mircescu G: Is hepcidin-25 a clinically relevant parameter for the iron status in hemodialysis patients? J Ren Nutr 2010, 20:S77-S83.
• [34]Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, Wetzels JF, Kiemeney LA, Sweep FC, den Heijer M, Swinkels DW: Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011, 117:e218-e225.
• [35]Delbini P, Vaja V, Graziadei G, Duca L, Nava I, Refaldi C, Cappellini MD: Genetic variability of TMPRSS6 and its association with iron deficiency anaemia. Br J Haematol 2010, 151:281-Äì284.